EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of first trimester maternal serum inhibin-A for preeclampsia screening

Sakita Moungmaithong iD, Angel H Kwan, Ada W Tse, Natalie K Wong, Michelle S Lam, Jing Wang, Liona C Poon iD, Daljit S Sahota

PLOS ONE · 10.07.2023 · 18 (7) · e0288289

DOI: 10.1371/journal.pone.0288289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 10.07.2023. Verfasst von Sakita Moungmaithong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Pre-Eclampsia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese University of Hong Kong, Health and Medical Research Fund, Ministry of Science and Technology of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

International professional organizations recommend aspirin prophylaxis to women screened high risk for preterm preeclampsia (PE) in the first trimester. The UK Fetal Medicine Foundation (FMF) screening test for preterm PE using mean arterial pressure (MAP), uterine artery pulsatility index (UTPI) and placental growth factor (PlGF) was demonstrated to have lower detection rate (DR) in Asian population studies. Additional biomarkers are therefore needed in Asian women to improve screening DRs as a significant proportion of women with preterm and term PE are currently not identified.

Objectives

To evaluate maternal serum inhibin-A at 11–13 weeks as an alternative to PlGF or as an additional biomarker within the FMF screening test for preterm PE. Study design This is a nested case-control study using pregnancies initially screened at 11–13 weeks for preterm PE using the FMF triple test in a non-intervention study conducted between December 2016 and June 2018. Inhibin-A levels were retrospectively measured in 1,792 singleton pregnancies, 112 (1.7%) with PE matched for time of initial screening with 1,680 unaffected pregnancies. Inhibin-A levels were transformed to multiple of the expected median (MoM). The distribution of log 10 inhibin-A MoM in PE and unaffected pregnancies and the association between log 10 inhibin-A MoM and gestational age (GA) at delivery in PE were assessed. The screening performance determined by area under receiver operating characteristic curves (AUC) and detection rates (DRs) at a 10% fixed false positive rate (FPR), for preterm and term PE was determined. All risks for preterm and term PE were based on the FMF competing risk model and Bayes theorem. Differences in AUC (ΔAUC) between different biomarker combinations were compared using the Delong test. McNemar’s test was used to assess the off-diagonal change in screening performance at a fixed 10% FPR after adding inhibin-A or replacing PlGF in the preterm PE adjusted risk estimation model.

Results

Inhibin-A levels in unaffected pregnancies were significantly dependent on GA, maternal age and weight and were lower in parous women with no previous history of PE. Mean log 10 inhibin-A MoM in any-onset PE (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-EclampsiaPregnancyInfant, NewbornFemaleHumansPregnancy Trimester, FirstBayes TheoremCase-Control StudiesRetrospective StudiesPlacenta Growth FactorRisk AssessmentBiomarkersUterine ArteryPulsatile Flow

Substanzen

Placenta Growth FactorBiomarkers

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Department of Obstetrics and Gynaecology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China.

ORCID-Profile: Sakita Moungmaithong, Liona C Poon

Förderung

  • Chinese University of Hong Kong
  • Health and Medical Research Fund
  • Ministry of Science and Technology of the People's Republic of China

Zitieren

APA

Moungmaithong, S., Kwan, A. H., Tse, A. W., Wong, N. K., Lam, M. S., Wang, J., Poon, L. C., & Sahota, D. S. (2023). Evaluation of first trimester maternal serum inhibin-A for preeclampsia screening. PLOS ONE, 18(7), e0288289. https://doi.org/10.1371/journal.pone.0288289

Vancouver

Moungmaithong S, Kwan AH, Tse AW, Wong NK, Lam MS, Wang J, et al. Evaluation of first trimester maternal serum inhibin-A for preeclampsia screening. PLOS ONE. 2023;18(7):e0288289. doi:10.1371/journal.pone.0288289

BibTeX
@article{Moungmaithong2023,
  author = {Moungmaithong, Sakita and Kwan, Angel H and Tse, Ada W and Wong, Natalie K and Lam, Michelle S and Wang, Jing and Poon, Liona C and Sahota, Daljit S},
  title = {Evaluation of first trimester maternal serum inhibin-A for preeclampsia screening},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {7},
  pages = {e0288289},
  doi = {10.1371/journal.pone.0288289}
}
Kostenlos starten →